Cipla launches Corona virus generic drug, price not revealed

New Delhi The country's renowned pharmaceutical company Cipla has made a generic drug of remedisvir for the treatment of corona virus patients. The company has offered the generic version 'Ciprami', which has been approved by the US drug regulator USFDA for emergency of Kovid-19 patients.

The only USFDA approved drug
The USFDA has given Gilead Sciences an Emergency Use Approval (EUA) for the emergency use of Remadecivir to treat Kovid-19 patients. Remadecivir is the only drug the USFDA has approved for emergency use for the treatment of Kovid-19 patients.

Agreement was done in may
Gilead Sciences in May signed a non-exclusive license agreement with Cipla for the manufacture and marketing of Remedisvir. Cipla said that he has received limited permission from the Controller General of India (DCGI) to use this medicine in an emergency.

The company said in a statement that “Under the risk management plan, Cipla will train the use of the drug and check the patient's consent documents and complete monitoring after marketing, as well as a fourth phase clinical trial on Indian patients. Will do.

Also read: Will you get money if you are corona positive? This new scheme is coming soon for you

Government will supply in the open market
The company said that this drug will be supplied through the government and the open market. On launching this drug, Global CEO Umang Vohra, managing director of Cipla Ltd said, “Cipla appreciates the strong partnership with Gilead for the treatment of patients in India. We have invested a lot in search of all possible ways to save the lives of millions affected by the Kovid-19 pandemic and this offering is an important step in that direction. ”

See also —